CTSO · Cytosorbents Corporation

Summary

CytoSorbents Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2025, reporting full-year revenue of $37.1 million, up 4% from $35.6 million in 2024, and net loss of $8.2 million or $0.13 per share. Highlights include $2.5 million proceeds from an amended credit facility, Q4 cost reduction program, over 300,000 cumulative CytoSorb treatments, and ongoing FDA discussions for a new DrugSorb-ATR De Novo application.

Key takeaways

• 2025 revenue $37.1 million, up 4% from $35.6 million in 2024
• 2025 gross margin 71% vs 70% in 2024
• 2025 net loss $8.2 million or $0.13 per share, improved from $20.7 million or $0.38 per share in 2024
• Q4 2025 revenue $9.2 million, up 1% year-over-year
• Total cash, cash equivalents, and restricted cash $7.8 million as of December 31, 2025
• Additional $2.5 million proceeds from amended credit facility in November 2025